Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia
Amgalan Byambasuren(Mongolian National University of Medical Sciences), Oidov Baatarkhuu(Mongolian National University of Medical Sciences)
Cited by 3
Related Papers
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
|The Lancet. Gastroenterology & hepatology|2023|399
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
|Hepatology International|2020|295
The present and future disease burden of hepatitis <scp>C</scp> virus (<scp>HCV</scp>) infections with today's treatment paradigm – volume 2
|Journal of Viral Hepatitis|2015|125
Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories
|Journal of Hepatology|2023|94
Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in select countries – volume 2
|Journal of Viral Hepatitis|2015|93